Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis

IgA Nephropathy 
Searching for companies focused on treating severe diseases that have yet to find approved drugs is one of Prohost Biotech's tasks.  Recently we wrote about firms that have, in their pipelines, products that aim at treating NASH and ALS.  Now, we are currently interested in finding firms that have products that can successfully treat IgA nephropathy, among other diseases that have yet to find treatments.

We will tackle these diseases in the upcoming Prohost . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.